Vaccine Boost to Strengthen Immunotherapy for Advanced Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding a COVID-19 vaccine can help immunotherapy (pembrolizumab) work better for people with advanced non-small cell lung cancer. Researchers believe boosting the immune system this way may improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have stage IV (advanced) non-small cell lung cancer diagnosed by biopsy or tissue sample
- Your doctor thinks you're healthy enough for pembrolizumab chemotherapy (ECOG score 0–2, meaning you can do most daily activities)
- You're willing to receive the Pfizer-BioNTech COVID-19 vaccine as part of the study
- You don't have any other active cancers that would interfere with this treatment
- If you can get pregnant, you agree to use birth control during treatment and for 5 months after your last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies pembrolizumab (an immune-boosting cancer medicine) alone or with an added investigational UV1 vaccine in people with advanced non-small cell lung cancer. It aims to see whether adding the vaccine improves safety and effectiveness, especially in tumors with high PD-L1 levels.
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with the immunotherapy drug adebrelimab for people with non-small cell lung cancer. It may help your immune system fight cancer cells that remain after standard treatment.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
Hear when a new Stage 4 NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.